Related content

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): A comparison of interferon beta therapies for relapsing-remitting multiple sclerosis

By Limmroth Volker   Malessa Rolf   Zettl Uwe   Koehler Jürgen   Japp Gudrun   Haller Peter   Elias Wolfgang   Obhof Winfried   Viehöver Andrea   Meier Uwe   Brosig Arne   Hasford Joerg   Putzki Norman   Kalski Gabriele   Wernsdörfer Colin  

Journal of Neurology, Vol. 254, Iss. 1, 2007-01 ,pp. : 67-77

Springer Publishing Company

Access to resources Recommend Favorite

Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis

By Rejdak K.   Petzold A.   Kocki T.   Kurzepa J.   Grieb P.   Turski W. A.   Stelmasiak Z.  

Journal of Neural Transmission, Vol. 114, Iss. 8, 2007-08 ,pp. : 1011-1015

Springer Publishing Company

Access to resources Recommend Favorite

Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome

By Sladkova Vladimira   Mareš Jan   Lubenova Blanka   Zapletalova Jana   Stejskal David   Hlustik Petr   Kanovsky Petr  

Neurological Research, Vol. 33, Iss. 4, 2011-05 ,pp. : 415-420

Maney Publishing

Access to resources Recommend Favorite

Development of laquinimod for relapsing––remitting multiple sclerosis

By Jeffery Douglas R  

Future Neurology, Vol. 3, Iss. 6, 2008-11 ,pp. : 641-648

Future Medicine

Access to resources Recommend Favorite

Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study

By Zivadinov Robert   Ramanathan Murali   Ambrus Julian   Hussein Sara   Ramasamy Deepa P   Dwyer Michael G   Bergsland Niels   Minagar Alireza   Weinstock-Guttman Bianca  

Neurological Research, Vol. 34, Iss. 8, 2012-10 ,pp. : 761-769

Maney Publishing

Access to resources Recommend Favorite